RESUMEN
Objective@#To investigate the incidence of adverse event following immunization (AEFI) with 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) in Jiaxing City, Zhejiang Province, so as to provide insights into safety monitoring and evaluation of PCV13.@*Methods@#Surveillance data of AEFI with PCV13 in Jiaxing City from 2020 to 2022 were collected from the AEFI Monitoring Information Management System of the Immunization Planning System of Chinese Disease Prevention and Control Information System, including demographic information, vaccination time, time of AEFI occurrence and clinical symptoms, and the reported incidence, population and district distribution, and clinical symptoms of AEFI with PCV13 were descriptively analyzed.@*Results@#Totally 455 cases of AEFI with PCV13 were reported in Jiaxing City from 2020 to 2022, with a reported incidence rate of 232.33/105 doses. There were 431, 21 and 3 cases of general, abnormal, coincidence and psychogenic reactions, with reported incidence rates of 220.07/105 doses, 10.72/105 doses and 1.53/105 doses, respectively, and no reports of causal reaction, vaccine quality accident and vaccination accident. The AEFI cases included 258 boys and 197 girls, with a boy/girl ratio of 1.31∶1, and 288 children at ages of less than a year (63.30%). The largest number of AEFI was reported in Haining City (87 cases, 19.12%), and there were 349 AEFI cases (76.70%) within 24 hours following vaccination. The clinical symptoms mainly included redness and swelling, fever and induration, with reported incidence rates of 132.76/105 doses (260 cases), 109.27/105 doses (214 cases), and 55.66/105 doses (109 cases), respectively. There were 450 cases cured and 5 cases improved in 455 cases of AEFI.@*Conclusions@#General reaction is the predominant AEFI in Jiaxing City from 2020 to 2022, with mild symptoms. Most AEFI occurs within 24 hours following vaccination, and has a good prognosis.
RESUMEN
Objective@#To analyze the surveillance of adverse event following immunization (AEFI) among 8-month-old children in Jiaxing who received measles, mumps and rubella combined attenuated live vaccine (MMR) or measles and rubella combined attenuated live vaccine (MR) , so as to provide support for the adjustment of vaccine immunization strategy.@*Methods @#The AEFI information of MR (December 1, 2016 to April 30, 2018) and MMR (December 1, 2018 to April 30, 2020) was collected through National AEFI Monitoring Information Management System to compare the incidence, clinical features, occurred time of AEFI as well as combined vaccination.@*Results@#Totally 94 287 doses of MR and 79 994 doses of MMR were administered, 145 and 156 cases of AEFI were reported, and the incidence rate was 15.38/10 000 after MR vaccination, which was lower than 19.50/10 000 after MMR vaccination (P<0.05). Most reported AEFI were abnormal reactions, with 93 cases (11.63/10 000) after MR vaccination and 101 cases (10.71/10 000) after MMR vaccination, among which 72 cases (7.64/10 000) and 76 cases (9.50/10 000) respectively had allergic rash. The AEFI cases mainly occurred less than one day after vaccination, with 113 cases (77.93%) after MR vaccination and 125 cases (80.13%) after MMR vaccination. Most cases of AEFI were vaccinated with Japanese encephalitis attenuated live vaccine (JEV), with 103 cases (71.03%) after MR vaccination and 102 cases (65.38%) after MMR vaccination.@*Conclusions@#The MMR is safety for 8-month-old children in Jiaxing. Most AEFI cases had abnormal reactions, occur within one day after vaccination, and are vaccinated with JEV.